1. Home
  2. DHC vs MLYS Comparison

DHC vs MLYS Comparison

Compare DHC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DHC
  • MLYS
  • Stock Information
  • Founded
  • DHC 1998
  • MLYS 2019
  • Country
  • DHC United States
  • MLYS United States
  • Employees
  • DHC N/A
  • MLYS N/A
  • Industry
  • DHC Real Estate Investment Trusts
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • DHC Real Estate
  • MLYS Health Care
  • Exchange
  • DHC Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • DHC 856.4M
  • MLYS 890.6M
  • IPO Year
  • DHC N/A
  • MLYS 2023
  • Fundamental
  • Price
  • DHC $3.36
  • MLYS $13.00
  • Analyst Decision
  • DHC Sell
  • MLYS Strong Buy
  • Analyst Count
  • DHC 2
  • MLYS 4
  • Target Price
  • DHC $3.00
  • MLYS $27.00
  • AVG Volume (30 Days)
  • DHC 940.0K
  • MLYS 681.4K
  • Earning Date
  • DHC 08-04-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • DHC 1.18%
  • MLYS N/A
  • EPS Growth
  • DHC N/A
  • MLYS N/A
  • EPS
  • DHC N/A
  • MLYS N/A
  • Revenue
  • DHC $1,522,835,000.00
  • MLYS N/A
  • Revenue This Year
  • DHC $3.98
  • MLYS N/A
  • Revenue Next Year
  • DHC $4.50
  • MLYS N/A
  • P/E Ratio
  • DHC N/A
  • MLYS N/A
  • Revenue Growth
  • DHC 4.29
  • MLYS N/A
  • 52 Week Low
  • DHC $2.00
  • MLYS $8.24
  • 52 Week High
  • DHC $4.24
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • DHC 44.73
  • MLYS 41.37
  • Support Level
  • DHC $3.18
  • MLYS $12.86
  • Resistance Level
  • DHC $3.53
  • MLYS $13.70
  • Average True Range (ATR)
  • DHC 0.12
  • MLYS 0.74
  • MACD
  • DHC -0.01
  • MLYS -0.09
  • Stochastic Oscillator
  • DHC 48.65
  • MLYS 12.24

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: